Safety and Immunogenicity Study of Rabies G Protein Vaccine Administered as a Simulated Post-exposure Immunization in Healthy Volunteers.

Trial Profile

Safety and Immunogenicity Study of Rabies G Protein Vaccine Administered as a Simulated Post-exposure Immunization in Healthy Volunteers.

Planning
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Rabies G protein vaccine (Primary)
  • Indications Rabies
  • Focus Adverse reactions
  • Sponsors Cadila Pharmaceuticals
  • Most Recent Events

    • 18 Jul 2014 Planned number of patients changed to 170 as reported by Clinical Trials Registry - India.
    • 03 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top